The Food Safety and Standards Authority of India (FSSAI) has initiated legal action against Nestle India, seeking clarifications on specific promotional claims for its infant nutrition products, NAN Excella Pro and Lactogen Pro. The regulatory body’s scrutiny, first reported by Livemint and The Hindu on September 19, 2026, focuses on claims related to ‘5HMOs’ and ‘Whey Protein’ used in advertising these infant formulas.

Nestle India quickly responded to the FSSAI’s action, stating its full adherence to all applicable laws and regulations in the country. The company confirmed it continues to engage with the FSSAI regarding the matter, defending its products against the allegations of non-compliance. This immediate and firm defense shows how sensitive health claims are for infant food products, and how strict their regulation is.

The Regulatory Scrutiny and Nestle’s Stance

The FSSAI’s legal action is a clear step in ensuring transparency and accuracy in product claims, particularly for vulnerable consumer segments like infants. The authority’s focus on ‘5HMOs’ and ‘Whey Protein’ claims suggests a detailed examination of the scientific substantiation behind nutritional benefits advertised to parents. For startups in the growing health and food-tech sectors, this incident shows the FSSAI’s proactive approach to regulating marketing practices. Any company making health or nutritional claims for its products must ensure these claims are scientifically sound. This is especially true for those aimed at children or specific health outcomes. All claims must be fully compliant with FSSAI regulations.

Nestle India’s response, as reported by Livemint, consistently emphasizes “adherence to regulations.” This mirrors the standard corporate response to regulatory challenges. Companies acknowledge the inquiry while maintaining compliance. The company’s engagement with FSSAI will likely involve providing detailed documentation and scientific evidence to support its claims for NAN Excella Pro and Lactogen Pro. This process is a common part of regulatory oversight. Authorities seek clarification and companies provide substantiation.

Implications for Indian Startups in Food and Health Tech

While Nestle India is a multinational giant, the FSSAI’s action carries broader implications for Indian startups, particularly those innovating in food products, dietary supplements, and health-focused consumables. The scrutiny shows several critical areas for compliance:

  • Substantiation of Claims: Every health or nutritional claim, no matter how small, must be backed by verifiable scientific evidence. Startups often aim for rapid market entry. This incident shows that cutting corners on substantiation can lead to significant legal and reputational risks.
  • Clear Communication: The language used in marketing and packaging needs to be unambiguous and not misleading. Vague or overly enthusiastic descriptions can attract regulatory attention. This applies even if they are technically true in a narrow context, but imply benefits beyond what can be proven.
  • Proactive Engagement: Companies should maintain open channels with regulatory bodies like FSSAI. Understanding and anticipating regulatory expectations helps design products and marketing strategies that are compliant from the outset.

This ongoing interaction between FSSAI and Nestle India shows that regulatory bodies actively monitor product claims. For startups, this means investing in strong legal and compliance teams early on, ensuring that product development and marketing are aligned with regulatory frameworks. The cost of non-compliance, including potential legal penalties and damage to consumer trust, far outweighs the initial investment in thorough regulatory vetting. The FSSAI’s clear focus on specific claims for infant nutrition products shows a zero-tolerance approach to any perceived misrepresentation. This sets a high bar for all players in the food industry.

The FSSAI’s legal action against Nestle India, initiated on September 19, 2026, and Nestle India’s subsequent defense, shows the ongoing vigilance of Indian regulators over product claims. Startups and established companies alike must ensure their marketing and product descriptions are rigorously compliant, particularly when dealing with health and nutrition benefits. Strict adherence to regulatory standards is a fundamental requirement for operating in the Indian food and health sectors.

What is FSSAI’s action against Nestle India?

FSSAI has initiated legal action against Nestle India, seeking clarifications on promotional claims related to ‘5HMOs’ and ‘Whey Protein’ for its infant nutrition products, NAN Excella Pro and Lactogen Pro.

What is Nestle India’s response?

Nestle India has stated that its infant nutrition products, NAN Excella Pro and Lactogen Pro, are in full compliance with all FSSAI regulations and that the company continues to engage with the authority on the matter.

Compiled by Launch91 Desk from the sources linked above. More about Launch91.